TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of patients agreeing to modified treatment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: change in current intensity for positive Tsui test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Vital Signs of Potential Clinical Importance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients cured of SIBO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Visualization of detected focal liver lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of PCR Negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of SARS-CoV-2 genomic RNA in sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiostereometric Analysis (RSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Night Time Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frailty according to L.Fried criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity according to Barthel score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity according to Timed up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: monthly ESA dose per dry body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EuroQol-5 Dimensions (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NASS patient satisfaction scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: functional success of microdialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DASH Score Change from Baseline
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Non-ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Tinnitus Handicap Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in total kidney volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Weight Change (kg) From Baseline to Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADHD-RS-IV Total Score at Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADHD-RS-IV Total Score at Week 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative axial movement of predeployed stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Drug-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variation in pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of 20 mg GSK557296
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of 150 mg GSK557296
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of GSK557296
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term safety of risperidone
Endpoint domain: Adverse events/effects
Primary endpoint: Manifestations of the metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Steps taken per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amniotic fluid index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival (PFS) From Initial Metastatic Diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) From Metastatic Diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of Major depressive Disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Trunk flexor & extensor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Yield of Capillary Technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Yield of Standard Technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of EUS-FNA With Capillary Technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of EUS-FNA With Standard Technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of EUS-FNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Visual Analogue Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum Depression Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical malaria or subclinical infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Measurement of liver enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Fatigue Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rate of forearm wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in composite score of vocational tasks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in at home medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: major adverse cardiac or cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients remaining free of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of Hypogonadism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of All Hemorrhages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Major Hemorrhages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Minor Hemorrhages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urine Neutrophil Gelatinase-associated Lipocalin (NGAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Local failure within irradiation volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in serum PRL concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: positive parenting practices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain intensity measured by VAS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of ExpiredCO Level From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Nicotine Dependence by Treatment Assignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mammography Uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Hemoglobin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Mean Asthma Control Questionnaire (ACQ) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caspofungin pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Distance walked before onset of intermittent claudication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Amount of local anesthetic drug required to maintain VAS score < 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention Rate After 12 Months of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Insulin production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Family Role Performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Care Management Strategies
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Family Caregiver Conflict
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Family Function
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Participant Dropout Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hypnotic Discontinuation Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Hyperglycemia Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Severe Hypoglycemic Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive Function Measured by MCCB Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Function as Measured by the UPSA-B Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients requiring mechanical ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Motor Function Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline DNA methylation analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline oxidative stress determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Post-treatment subjective symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to recurrent biliary obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in mean night time blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Fentanyl Usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events (AEs) Possibly or Probably Related to BAX326
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of clinical signs and symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent correct for target speech sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Successfully Use ZEMY
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of toe-walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder base elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in cancer related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Gastrointestinal Symptoms Rating Scale (GSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Visual Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Energy expenditure adjusted by caloric density of milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Longitudinal strain of the free wall right ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: methods of applications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: dosing schedules
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Agreement in corneal epithelial thickness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Predicted Trajectory of Mean BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Predicted Trajectory of Mean Body Fat Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of treatment seeking for suspected PD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Leptin changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adiponectin changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Consumption of Oxygen (mlO2/kg/Min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Stress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative fever incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Sensory neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain Changes from Baseline on Functional and Structural Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients Experiencing Major Adverse Events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Detectable Serum Lidocaine Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients up-to-date for colorectal cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HYLENEX-facilitated Subcutaneous (SC) Rehydration Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response rate (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retinal microcirculation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss-of-response
Endpoint domain: Adverse events/effects
Primary endpoint: Occult cancer or precancerous lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean mid-facial recession coverage (mRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vital signs after first [68]Ga-HA-DOTATATE injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in haematology and biochemistry after first [68]Ga-HA-DOTATATE injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Motor function of the paretic upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory function of the paretic upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of SHR1459
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of SHR1459
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endocrine sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Total Score of Gross Motor Function Measure (GMFM)-88
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gross Motor Function Measure (GMFM)-66 Percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in self-management scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oxygen uptake (VO2) during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of brain MRI for follow-up of treated brain AVM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hot Flash Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot Flash Bother
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Bone Mineral Density (BMD) in the Spine at End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Bone Mineral Density (BMD) in the Femur at End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Major recurrent cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Health-related QoL (EQ-5D-3L overall health utility score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pathology findings in liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Pathology findings in pancreatic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of topical ALT-2074 in treating chronic plaque psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Postoperative success of penile revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative difference in change of K+Sa at t2 versus t1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG P wave height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ECG PR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ECG QRS duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ECG maximum R wave height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ECG QT interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hamilton Depression Rating Scale (HAM-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of 'on' stimulation time without dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burke-Fahn-Marsden Dystonia Rating Scale-Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toronto Western Spasmodic Torticollis Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion of ankle dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle of projection in the frontal plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with response at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total expenses related to Crohn's disease during the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline upper esophageal sphincter pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: hematological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with childhood or suspected familial thyroid nodules/cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of germline mutations identified associated with thyroid cancer predisposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of suspected familial thyroid cancer among those with childhood thyroid nodules/cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasticity (ratio between excitatory to inhibitory brain response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Connectivity (dispersion of brain signal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic performance of blood-based assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Validity and reliability of HDRS-17
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Load Carriage Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical Jump Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Mass Lifted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes